A Huge Shift Is Underway in America
Many Americans say they no longer recognize the country they grew up in.
With more and more haunting news confirming their fears every day.
Now, a former $200 million hedge fund firm manager has just issued a chilling new warning:
"The market is soaring this year... but we're not in a bubble," says Whitney Tilson. "This is something far more dangerous, and it's changing everything we know about money."
Tilson - who predicted both the 2008 crash and the 2020 market bottom - says a massive shift is underway inside our financial system... and 99% of Americans are unprepared.
"If you still believe you'll get ahead by owning ordinary stocks and mutual funds," he says, "you're going to be blindsided."
This shift is already creating millionaires and billionaires at the fastest pace in history.
CNBC calls it "the largest wealth creation spree in history."
And yet, 1 in 3 Americans say their financial situation has deteriorated over the past year.
"We're seeing the rise of one-person companies worth billions," Tilson says. "The rules have changed. The old playbook is dead."
Tilson just revealed a unique way to get ahead of this change, and protect yourself from what comes next.
With his permission, we've posted his full public briefing on our website, free of charge.
Regards,
Matt Weinschenk
Director of Research, Stansberry Research
3 Healthcare Stocks Using AI to Drive Growth
Written by Chris Markoch. Published 9/27/2025.
Key Points
- Discover how three healthcare companies use AI to improve patient outcomes and reduce physician burnout.
- Learn why Hims & Hers, Tempus AI, and Boston Scientific are positioned for growth as AI adoption accelerates.
- See how AI is transforming telehealth, precision medicine, and medical devices to drive efficiency in healthcare.
Artificial intelligence (AI) is reshaping industries much like the internet did three decades ago. Beyond enhancing search, AI is streamlining administrative workflows across sectors—and healthcare is undergoing one of the most significant transformations.
Generative and agentic AI tools are empowering physicians and care teams with more accurate diagnoses, automated paperwork and reduced burnout. According to Athenahealth's third Physician Sentiment Survey, 93% of physicians regularly experience burnout.
This rock I'm holding could be worth trillions (Ad)
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems.
While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.
With an aging population intensifying the supply-and-demand imbalance, AI solutions can help bridge efficiency gaps while maintaining personalized care.
That makes now a prime time for investors to look at companies already leveraging AI to drive better outcomes and streamline operations. Here are three healthcare stocks poised for future growth thanks to AI-driven catalysts.
AI-Enhanced Telehealth at Scale
Hims & Hers Health Inc. (NYSE: HIMS) has been one of 2025's top performers, climbing 121% year-to-date and 29% over the past 30 days through September 24. While the meme-stock crowd helped fuel that rally, Hims & Hers offers a compelling long-term growth story.
As a telehealth provider, Hims & Hers is naturally aligned with AI adoption. The company uses machine learning to triage patient inquiries, automate follow-up reminders and expedite prescription refills—eliminating inefficiencies that can bog down virtual healthcare.
Trading at $53.86 per share (down roughly 21% from its February peak), HIMS has twice stalled near the $65 resistance level amid elevated volume and active short interest. Despite a consensus Hold rating, Canaccord Genuity reiterated a Buy rating on September 12 and set a $68 price target. For patient investors, HIMS stock could benefit from a sustained AI tailwind.
Precision Medicine and Oncology Insights
Tempus AI (NASDAQ: TEM) specializes in applying AI and machine learning to genomic, clinical and molecular data, helping develop tailored therapies and improve patient outcomes. The company's oncology-focused tools enable physicians to customize cancer treatment plans, predict patient responses and identify real-time clinical trial opportunities.
Tempus' data platform is widely adopted: 19 of the world's top 20 pharmaceutical firms utilize Tempus data for drug discovery. In September, the company received FDA 510(k) clearance for its RNA-based Tempus xR IVD device, expanding its capabilities in RNA sequencing.
Like HIMS, TEM experienced volatile trading in 2025—up 128% year-to-date and 17% over the past three months, but facing over 25% short interest and resistance around its all-time high of $89. Nevertheless, analysts remain bullish and continue to raise price targets.
Smarter Devices with AI Integration
Boston Scientific Corp. (NYSE: BSX) is leveraging AI within its medical devices and digital health solutions to automate monitoring, diagnostics and data processing. This allows clinicians to focus on patient care rather than administrative overhead.
A recent catalyst was the FDA's expanded approval of Boston Scientific's FARAPULSE pulsed field ablation system for treating certain forms of atrial fibrillation—an arrhythmia that affects nearly 60 million people worldwide. Since the announcement, at least two analysts have reiterated Buy ratings on BSX, setting price targets well above consensus.
BSX shares are up about 17% in 2025, roughly in line with the S&P 500. Though they haven't broken past their 52-week high like HIMS or TEM, the company's deep AI integration and recent approvals suggest upside potential as digital health adoption accelerates.
This email communication is a paid advertisement from Stansberry Research, a third-party advertiser of MarketBeat. Why did I receive this email?.
This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
If you need help with your subscription, please don't hesitate to contact MarketBeat's U.S. based support team at contact@marketbeat.com.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2025 MarketBeat Media, LLC. All rights protected.
345 N Reid Place #620, Sioux Falls, South Dakota 57103. U.S.A..